诺诚健华今日盘中股价大涨5.02%，引起市场广泛关注。
消息面上，公司于前一交易日盘后发布了2025年年度报告，业绩表现亮眼。报告显示，诺诚健华2025年实现营业收入23.75亿元，同比增长135.27%；归属于上市公司股东的净利润为6.42亿元，成功实现扭亏为盈。此外，公司第四季度单季净利润同比大幅增长527.84%。
除了优异的财务数据，公司的研发与商业化也取得重要进展。核心产品奥布替尼销售放量，坦昔妥单抗等新药获批上市，抗体偶联药物（ADC）平台取得突破，并且公司通过对外授权交易加速全球化布局。同时，公司A股股票将于近期取消特别标识“U”。这些积极的业绩与研发进展，共同提振了市场信心，推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.